SALT LAKE CITY, Jan. 15, 2015 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq: BSDM ) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today reported financial results for the fiscal first quarter of 2015 ended November 30, 2014.
Total revenues were $843,168 for the first quarter ended November 30, 2014, a decrease of 37% compared to total revenues of $1,330,645 for the three months ended November 30, 2013. Product sales in the three months ended November 30, 2013 included significant stocking orders from Terumo for MicroThermX® systems. The decrease in product sales revenues was partially offset by modest increases in sales of MicroThermX disposable devices and service contracts and other revenues, along with increases in rental of MicroThermX systems on a fee per use basis. During the three months ended November 30, 2014, BSD recognized partial revenue on one hyperthermia system. By comparison, during the three months ended November 30, 2013, BSD sold two hyperthermia systems.
Total gross margin was $392,339, or approximately 47% of total revenues, for the three months ended November 30, 2014 and $691,333, or approximately 52%, for the three months ended November 30, 2013. The decrease in gross margin and gross margin percentage in the three months ended November 30, 2014 compared to the three months ended November 30, 2013 resulted primarily from the decrease in product sales.
Operating expenses increased to $2.4 million for the first quarter of fiscal 2015 from $2.2 million for the comparable period last year. Research and development expenses declined to $469,719 for the first quarter of fiscal 2015, from $502,757 for the first quarter of fiscal 2014. Selling, general and administrative expenses for the first quarter of fiscal 2015 increased to $1,951,373 from $1,704,713 for the first quarter of fiscal 2014.
The Company reported a net loss of $2.0 million, or $0.05 per share, for the first quarter of fiscal 2015, compared to a net loss of $1.5 million, or $0.04 per share, for the first quarter of fiscal 2014.
As of November 30, 2014, BSD had cash and cash equivalents of $6.2 million and no long-term debt.
Effective November 10, 2014, BSD's Board of Directors appointed Clint Carnell, 45, President, Chief Executive Officer, and member of the Board of Directors. In a series of investor and analyst meetings being held this week in the San Francisco Bay Area, Carnell discussed his 60-day assessment of BSD and immediate change in direction for the Company. Going forward, BSD will focus on microwave ablation and plans to exit its hyperthermia business in 2015.
Subsequent to the end of the fiscal first quarter, the Board of Directors of BSD changed the Company's fiscal year end from August 31 to December 31, beginning December 31, 2014. The report covering the Company's transition period ended December 31, 2014 will be filed on Form 10-K.
Investor & Analyst Conference Call and Webcast Today at 2:00 p.m. Eastern time/12:00 p.m. Mountain time
Individuals interested in listening to the conference call may do so by visiting the Investor Relations section of the Company's website at www.BSDMedical.com or by dialing 800.860.2442 from the United States, or 412.858.4600 from outside the United States, and referencing "BSD Medical."
A telephone replay will be available through January 22, 2015, by dialing 877.344.7529 from the United States, or 412.317.0088 from outside the United States, and entering conference ID 10057961. A webcast replay will be available for 90 days.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. BSD's MicroThermX ® microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company's products have received regulatory approvals and clearances in the United States, Europe and China.
For further information visit BSD Medical's website at www.BSDMedical.com .
Forward-Looking Statements
Statements contained in this press release that are not historical facts, including statements relating to our 2015 and other future plans, our target treatment rate, and financial performance relating to microwave ablation are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the market demand for our MicroThermX products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
| BSD MEDICAL CORPORATION | ||
| Condensed Balance Sheets | ||
| (Unaudited) | ||
| ASSETS | November 30, 2014 | August 31, 2014 |
| Current assets: | ||
| Cash and cash equivalents | $ 6,206,193 | $ 8,130,416 |
| Accounts receivable, net of allowance for doubtful accounts of $20,000 | 345,263 | 366,887 |
| Related party trade accounts receivable | 5,888 | 8,322 |
| Inventories, net | 2,363,854 | 2,329,189 |
| Other current assets | 93,810 | 146,319 |
| Total current assets | 9,015,008 | 10,981,133 |
| Property and equipment, net | 1,238,181 | 1,267,661 |
| $ 10,253,189 | $ 12,248,794 | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $ 494,655 | $ 548,897 |
| Accrued liabilities | 845,878 | 866,528 |
| Note payable | 8,338 | 33,279 |
| Customer deposits | 41,667 | 41,781 |
| Deferred revenue | 67,288 | 96,043 |
| Total current liabilities | 1,457,826 | 1,586,528 |
| Total liabilities | 1,457,826 | 1,586,528 |
| Commitments and contingencies | ||
| Stockholders' equity: | ||
| Preferred stock, $.001 par value; 10,000,000 shares authorized, no shares issued and outstanding | -- | -- |
| Common stock, $.001 par value, 80,000,000 shares authorized, 39,713,540 shares issued | 39,714 | 39,714 |
| Additional paid-in capital | 63,559,661 | 63,394,556 |
| Treasury stock, 24,331 shares at cost | (234) | (234) |
| Accumulated deficit | (54,803,778) | (52,771,770) |
| Total stockholders' equity | 8,795,363 | 10,662,266 |
| $ 10,253,189 | $ 12,248,794 | |
| BSD MEDICAL CORPORATION | ||
| Condensed Statements of Comprehensive Loss | ||
| (Unaudited) | ||
| Three Months Ended November 30, | ||
| 2014 | 2013 | |
| Revenues: | ||
| Sales | $ 520,408 | $ 1,231,559 |
| Sales to related parties | 215,860 | 16,686 |
| Equipment rental | 106,900 | 82,400 |
| Total revenues | 843,168 | 1,330,645 |
| Cost of revenues: | ||
| Cost of sales | 316,542 | 628,711 |
| Cost of related party sales | 131,340 | 7,654 |
| Cost of equipment rental | 2,947 | 2,947 |
| Total cost of revenues | 450,829 | 639,312 |
| Gross margin | 392,339 | 691,333 |
| Operating costs and expenses: | ||
| Research and development | 469,719 | 502,757 |
| Selling, general and administrative | 1,951,373 | 1,704,713 |
| Total operating costs and expenses | 2,421,092 | 2,207,470 |
| Loss from operations | (2,028,753) | (1,516,137) |
| Other income (expense): | ||
| Interest income | 4,387 | 6,323 |
| Other income (expense) | (7,642) | (3,047) |
| Total other income (expense) | (3,255) | 3,276 |
| Loss before income taxes | (2,032,008) | (1,512,861) |
| Income tax benefit | -- | -- |
| Net loss and comprehensive loss | $ (2,032,008) | $ (1,512,861) |
| Net loss per common share: | ||
| Basic | $ (0.05) | $ (0.04) |
| Diluted | $ (0.05) | $ (0.04) |
| Weighted average number of shares outstanding: | ||
| Basic | 39,689,000 | 33,982,000 |
| Diluted | 39,689,000 | 33,982,000 |
| BSD MEDICAL CORPORATION | ||
| Condensed Statements of Cash Flows | ||
| (Unaudited) | ||
| Three Months Ended November 30, | ||
| 2014 | 2013 | |
| Cash flows from operating activities: | ||
| Net loss | $ (2,032,008) | $ (1,512,861) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 32,193 | 30,121 |
| Stock-based compensation | 165,105 | 216,229 |
| Decrease (increase) in: | ||
| Receivables | 24,058 | (266,923) |
| Inventories | (34,665) | (184,644) |
| Other current assets | 52,509 | 39,074 |
| Increase (decrease) in: | ||
| Accounts payable | (54,242) | (9,544) |
| Accrued liabilities | (20,650) | (157,840) |
| Customer deposits | (114) | 17,097 |
| Deferred revenue | (28,755) | (29,193) |
| Net cash used in operating activities | (1,896,569) | (1,858,484) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | (2,713) | (11,776) |
| Cash flows from financing activities: | ||
| Payments on note payable | (24,941) | -- |
| Net decrease in cash and cash equivalents | (1,924,223) | (1,870,260) |
| Cash and cash equivalents, beginning of period | 8,130,416 | 9,450,528 |
| Cash and cash equivalents, end of period | $ 6,206,193 | $ 7,580,268 |
Tricia Ross Financial Profiles 310-622-8226
